interactive session ovarian cancer ii
DESCRIPTION
Interactive Session Ovarian Cancer II Serous Borderline Tumors of the Ovary: Pathology, Biology, and Management. Jaime Prat, M.D. Nathalie Sieben, M.D. David Gershenson, M.D. Santa Monica, CA October 16, 2006. Surface epithelial ovarian tumors. - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: Interactive Session Ovarian Cancer II](https://reader036.vdocuments.net/reader036/viewer/2022062410/56816334550346895dd3bea1/html5/thumbnails/1.jpg)
Interactive Session Ovarian Cancer II
Serous Borderline Tumors of the Ovary: Pathology, Biology, and Management
Santa Monica, CAOctober 16, 2006
Jaime Prat, M.D.Nathalie Sieben, M.D.David Gershenson, M.D.
![Page 2: Interactive Session Ovarian Cancer II](https://reader036.vdocuments.net/reader036/viewer/2022062410/56816334550346895dd3bea1/html5/thumbnails/2.jpg)
Surface epithelial ovarian tumors
![Page 3: Interactive Session Ovarian Cancer II](https://reader036.vdocuments.net/reader036/viewer/2022062410/56816334550346895dd3bea1/html5/thumbnails/3.jpg)
Ovarian Epithelial Tumors ___________________________________________________________________________________________
Serous MucinousEndometrioidClear cellTransitional cellUndifferentiated
Benign60%
BL10%
Ca30%
![Page 4: Interactive Session Ovarian Cancer II](https://reader036.vdocuments.net/reader036/viewer/2022062410/56816334550346895dd3bea1/html5/thumbnails/4.jpg)
Serous Tumors of the Ovary
• Benign 70% • Borderline 5-10%• Carcinomas 20-25%
![Page 5: Interactive Session Ovarian Cancer II](https://reader036.vdocuments.net/reader036/viewer/2022062410/56816334550346895dd3bea1/html5/thumbnails/5.jpg)
• Epithelial hyperplasia• Nuclear atypia• Mitotic activity• NO “destructive” stromal invasion
Borderline Ovarian Tumors(Low Malignant Potential)
WHO 1973-2003
![Page 6: Interactive Session Ovarian Cancer II](https://reader036.vdocuments.net/reader036/viewer/2022062410/56816334550346895dd3bea1/html5/thumbnails/6.jpg)
Frequency 25-30% of Non-BgAge 30-50 yrsBilaterality 30%Stage I 70%
Serous Borderline Tumors
![Page 7: Interactive Session Ovarian Cancer II](https://reader036.vdocuments.net/reader036/viewer/2022062410/56816334550346895dd3bea1/html5/thumbnails/7.jpg)
SBT
![Page 8: Interactive Session Ovarian Cancer II](https://reader036.vdocuments.net/reader036/viewer/2022062410/56816334550346895dd3bea1/html5/thumbnails/8.jpg)
SBT
![Page 9: Interactive Session Ovarian Cancer II](https://reader036.vdocuments.net/reader036/viewer/2022062410/56816334550346895dd3bea1/html5/thumbnails/9.jpg)
Serous carcinoma
![Page 10: Interactive Session Ovarian Cancer II](https://reader036.vdocuments.net/reader036/viewer/2022062410/56816334550346895dd3bea1/html5/thumbnails/10.jpg)
Serous Borderline Tumor Serous Carcinoma
![Page 11: Interactive Session Ovarian Cancer II](https://reader036.vdocuments.net/reader036/viewer/2022062410/56816334550346895dd3bea1/html5/thumbnails/11.jpg)
Serous Borderline Tumor
1. Branching papillae 2. Variable nuclear atypia3. No stromal invasion
Diagnostic Features
![Page 12: Interactive Session Ovarian Cancer II](https://reader036.vdocuments.net/reader036/viewer/2022062410/56816334550346895dd3bea1/html5/thumbnails/12.jpg)
SBT - Micropapillary pattern
![Page 13: Interactive Session Ovarian Cancer II](https://reader036.vdocuments.net/reader036/viewer/2022062410/56816334550346895dd3bea1/html5/thumbnails/13.jpg)
![Page 14: Interactive Session Ovarian Cancer II](https://reader036.vdocuments.net/reader036/viewer/2022062410/56816334550346895dd3bea1/html5/thumbnails/14.jpg)
SBT - Micropapillary pattern
![Page 15: Interactive Session Ovarian Cancer II](https://reader036.vdocuments.net/reader036/viewer/2022062410/56816334550346895dd3bea1/html5/thumbnails/15.jpg)
Serous Borderline Tumors
Mean age 45 37Bilateral 22/96 (23) 12 (67)Exophytic growth 27/92 (29) 7/16 (44)
Stage I 78 (76) 5 (28) II+ 24 (24) 13 (72) (p = 0.0001)
Noninvasive implants 20 (83) 12 (92)Invasive implants 4 (17) 1 (8)
(a) Microinvasive + micropapillary (3 cases)
Prat J, de Nictolis M Am J Surg Pathol 2002
Typical Micropapillary n=102 (%) n=18 a (%)
![Page 16: Interactive Session Ovarian Cancer II](https://reader036.vdocuments.net/reader036/viewer/2022062410/56816334550346895dd3bea1/html5/thumbnails/16.jpg)
SBT - Micropapillary(More invasive implants?)
1999 Eichhorn et al Possible2002 Slomovitz et al No2002 Deavers et al Yes (17% vs 6%)2002 Prat & De Nictolis No2003 Gilks et al No2005 Longacre et al Yes
Overall survival similar to typical SBT
![Page 17: Interactive Session Ovarian Cancer II](https://reader036.vdocuments.net/reader036/viewer/2022062410/56816334550346895dd3bea1/html5/thumbnails/17.jpg)
Carcinoma (> 3 mm) in SBT-MP
![Page 18: Interactive Session Ovarian Cancer II](https://reader036.vdocuments.net/reader036/viewer/2022062410/56816334550346895dd3bea1/html5/thumbnails/18.jpg)
Cumulative literature: Excellent prognosisStanford data: Risk factor for disease progression
SBT with Microinvasion < 10 mm2
![Page 19: Interactive Session Ovarian Cancer II](https://reader036.vdocuments.net/reader036/viewer/2022062410/56816334550346895dd3bea1/html5/thumbnails/19.jpg)
• Stage• Florid epithelial proliferation (MP-cribriform pattern)• Microinvasion (?)• Type of peritoneal implants• Other factors yet unidentified
TA Longacre et alAm J Surg Pathol 2005
Serous Borderline Tumors(Risk of progression)
![Page 20: Interactive Session Ovarian Cancer II](https://reader036.vdocuments.net/reader036/viewer/2022062410/56816334550346895dd3bea1/html5/thumbnails/20.jpg)
Serous Borderline Tumors
Peritoneal Implants (30%)
![Page 21: Interactive Session Ovarian Cancer II](https://reader036.vdocuments.net/reader036/viewer/2022062410/56816334550346895dd3bea1/html5/thumbnails/21.jpg)
![Page 22: Interactive Session Ovarian Cancer II](https://reader036.vdocuments.net/reader036/viewer/2022062410/56816334550346895dd3bea1/html5/thumbnails/22.jpg)
Peritoneal Implants(SBT)
• Non-invasive- Epithelial- Desmoplastic
• Invasive Bell DA, et al Cancer 1988; 62:2212
![Page 23: Interactive Session Ovarian Cancer II](https://reader036.vdocuments.net/reader036/viewer/2022062410/56816334550346895dd3bea1/html5/thumbnails/23.jpg)
Noninvasive epithelial implant
![Page 24: Interactive Session Ovarian Cancer II](https://reader036.vdocuments.net/reader036/viewer/2022062410/56816334550346895dd3bea1/html5/thumbnails/24.jpg)
Noninvasive (desmoplastic) implant
![Page 25: Interactive Session Ovarian Cancer II](https://reader036.vdocuments.net/reader036/viewer/2022062410/56816334550346895dd3bea1/html5/thumbnails/25.jpg)
Invasive implant
![Page 26: Interactive Session Ovarian Cancer II](https://reader036.vdocuments.net/reader036/viewer/2022062410/56816334550346895dd3bea1/html5/thumbnails/26.jpg)
Invasive implant
![Page 27: Interactive Session Ovarian Cancer II](https://reader036.vdocuments.net/reader036/viewer/2022062410/56816334550346895dd3bea1/html5/thumbnails/27.jpg)
Invasive implant
![Page 28: Interactive Session Ovarian Cancer II](https://reader036.vdocuments.net/reader036/viewer/2022062410/56816334550346895dd3bea1/html5/thumbnails/28.jpg)
Serous Borderline Tumors
Non-invasive implants Invasive implants
McCaughey et al 2/13 4/5Bell DA et al 3/50 5/6De Nictolis et al 0/10 4/9 Kennedy and Hart 1/25 0/1Seidman and Kurman 1/51 2/3 Gershenson et al 6/73 6/39Eichhorn et al 0/30 2/3 Bell KA et al 2/29 6/31 Prat and de Nictolis 0/34 3/6 Longacre et al 2/75 5/14
20/390 (5%) 37/117 (32%)
(Death from tumor 1984-2005)
![Page 29: Interactive Session Ovarian Cancer II](https://reader036.vdocuments.net/reader036/viewer/2022062410/56816334550346895dd3bea1/html5/thumbnails/29.jpg)
Serous Borderline TumorsTwo hypotheses
![Page 30: Interactive Session Ovarian Cancer II](https://reader036.vdocuments.net/reader036/viewer/2022062410/56816334550346895dd3bea1/html5/thumbnails/30.jpg)
Serous Borderline Tumors
• 26 specimens from 10 patients• 23 microsatellite markers• Peritoneal implants (6 invasive, 4
noninvasive); lymph nodes (3) • Concordance in 22 tumors of 8
informative patients Sieben NLG et al J Pathol (in press) 2006
(Genome-wide allelotyping and B-RAF/K-RAS)
![Page 31: Interactive Session Ovarian Cancer II](https://reader036.vdocuments.net/reader036/viewer/2022062410/56816334550346895dd3bea1/html5/thumbnails/31.jpg)
Sieben N et al. J Pathol (in press) 2006
![Page 32: Interactive Session Ovarian Cancer II](https://reader036.vdocuments.net/reader036/viewer/2022062410/56816334550346895dd3bea1/html5/thumbnails/32.jpg)
Bord Stage Ca95% 1 54%91% 1-4 23%71% 2-4 20%
Serous Tumors(10 yr Survival)
![Page 33: Interactive Session Ovarian Cancer II](https://reader036.vdocuments.net/reader036/viewer/2022062410/56816334550346895dd3bea1/html5/thumbnails/33.jpg)
SBT in Lymph Nodes: 30%
LN: Mullerian cysts (endosalpingiosis)
SBT in lymph node
![Page 34: Interactive Session Ovarian Cancer II](https://reader036.vdocuments.net/reader036/viewer/2022062410/56816334550346895dd3bea1/html5/thumbnails/34.jpg)
Serous Borderline Tumor
Carcinoma
![Page 35: Interactive Session Ovarian Cancer II](https://reader036.vdocuments.net/reader036/viewer/2022062410/56816334550346895dd3bea1/html5/thumbnails/35.jpg)
TCCSBT 6th recurrence
![Page 36: Interactive Session Ovarian Cancer II](https://reader036.vdocuments.net/reader036/viewer/2022062410/56816334550346895dd3bea1/html5/thumbnails/36.jpg)
Epithelial Ovarian Cancer(Pathogenesis)
• Serous Borderline - B-RAF, K-RAS• Serous Ca - p53, LOH 17q21 (BRCA1),
13q12-q14 (BRCA2, RB1)• Mucinous tumors - K-RAS• Endometrioid Ca - Beta-catenin, PTEN, PIK3CA, Microsatellite instability
![Page 37: Interactive Session Ovarian Cancer II](https://reader036.vdocuments.net/reader036/viewer/2022062410/56816334550346895dd3bea1/html5/thumbnails/37.jpg)
Expression Profiling of Serous Low Malignant Potential, Low-Grade, and High-Grade Tumors of the Ovary.Bonome T, et al. Cancer Res 2005; 65:10602
Overexpressed in SBT and Low-Grade Carcinoma• p53• p21• Cyclin D1• CIRP• c-FOS
Overexpressed in High-Grade Carcinoma• Cyclin E• CD20• STAT-1• Apoliprotein E• Rsf-1
![Page 38: Interactive Session Ovarian Cancer II](https://reader036.vdocuments.net/reader036/viewer/2022062410/56816334550346895dd3bea1/html5/thumbnails/38.jpg)
Sieben N et al, J Clin Oncol 2005
![Page 39: Interactive Session Ovarian Cancer II](https://reader036.vdocuments.net/reader036/viewer/2022062410/56816334550346895dd3bea1/html5/thumbnails/39.jpg)
Sieben N et alJ Clin Oncol 2005
![Page 40: Interactive Session Ovarian Cancer II](https://reader036.vdocuments.net/reader036/viewer/2022062410/56816334550346895dd3bea1/html5/thumbnails/40.jpg)
High GradeSBT
L G
Ovarian Serous Tumors
![Page 41: Interactive Session Ovarian Cancer II](https://reader036.vdocuments.net/reader036/viewer/2022062410/56816334550346895dd3bea1/html5/thumbnails/41.jpg)
SBT + MPSCa
![Page 42: Interactive Session Ovarian Cancer II](https://reader036.vdocuments.net/reader036/viewer/2022062410/56816334550346895dd3bea1/html5/thumbnails/42.jpg)
MPSCa
SBT + MPSCa
![Page 43: Interactive Session Ovarian Cancer II](https://reader036.vdocuments.net/reader036/viewer/2022062410/56816334550346895dd3bea1/html5/thumbnails/43.jpg)
Serous Tumors(Pathogenesis - Dualistic model)
Serous Ca
KRAS and BRAF mutations (70%)
G3
G1-2MP Ca (Inv)SBT-MPSBTBg
Singer et alAm J Pathol 2002
p53 mutations, LOH 17q (80%)
HER-2/neu amplification/overexpression
![Page 44: Interactive Session Ovarian Cancer II](https://reader036.vdocuments.net/reader036/viewer/2022062410/56816334550346895dd3bea1/html5/thumbnails/44.jpg)
SBTs and Serous Carcinomas • SBT-MP pattern is a risk factor within the SBT category
rather than a separate category. Poor prognosis only with invasive implants.
• Non-invasive implants, common and benign• Invasive implants, rare (12%) and fatal (clonal)• Serous dualistic model (working guide)• Low grade serous carcinomas are rare (B-Raf, K-ras)• High grade serous carcinomas are common (p53, LOH,
chromosomal instability)
![Page 45: Interactive Session Ovarian Cancer II](https://reader036.vdocuments.net/reader036/viewer/2022062410/56816334550346895dd3bea1/html5/thumbnails/45.jpg)